Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

Swedish Evaluation of Left Ventricular Assist Device as Permanent Treatment in End-stage Heart Failure

NCT: NCT02592499 · ACTIVE_NOT_RECRUITING

NCT IDNCT02592499
StatusACTIVE_NOT_RECRUITING
SponsorVastra Gotaland Region (OTHER_GOV)
First posted
Last updated

Brief Summary

The study is a prospective, randomized, non-blinded, national, multi-center study. The study will consist of the assignment of eligible patients to treatment with either a HeartMate III (HM III) left ventricular assist device system or to pharmacological treatment (optimal medical management, OMM) according to current guidelines. Eighty (80) patients will be enrolled in this study and randomized in a 1:1 fashion between the HM III and OMM, based on a modified power calculation.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑